Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A DECKER

Showing results (671-680 of 718) with videos related to

Pageof 72
Sort By:
Neuro-Oncology|February 28, 2026
DNA copy number patterns reveal prognostic markers and elucidate mechanisms of evolution in IDH-mutant astrocytomaKristen L Drucker, Arijit Panda, Paul A Decker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2024
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma ModelsSonia Jain, Jessica I Griffith, Kendra A Porath, et al.
Neuro-Oncology Advances|July 25, 2025
Dissecting the biology of gliomagenesis: Evaluating the interaction between <i>IDH</i> tumor mutation and germline variantsMatthew L Kosel, Paul A Decker, Thomas M Kollmeyer, et al.
Molecular Cancer Research : MCR|February 22, 2022
Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL InhibitionMasum Rahman, Ian Olson, Moustafa Mansour, et al.
Neuro-Oncology Advances|March 30, 2026
Comparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma, <i>IDH</i>-wildtypeDaniel H Lachance, Paul A Decker, Thomas M Kollmeyer, et al.
Molecular Cancer Therapeutics|January 15, 2024
Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis XenograftsJianxiong Ji, Sonja Dragojevic, Cameron M Callaghan, et al.
Journal of the National Cancer Institute|November 29, 2015
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of GlioblastomaShiv K Gupta, Sani H Kizilbash, Brett L Carlson, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 13, 2016
Development and impact of arrhythmias after the Norwood procedure: A report from the Pediatric Heart NetworkMatthew E Oster, Shan Chen, Nicholas Dagincourt, et al.
Medrxiv : the Preprint Server for Health Sciences|April 29, 2025
Cerebrospinal fluid D-2-hydroxyglutarate for IDH-mutant glioma: utility for detection versus monitoringCecile Riviere-Cazaux, Yuta Suzuki, Zain Kizilbash, et al.
Neuro-Oncology Advances|February 10, 2026
Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenograftsRachael A Vaubel, Wenjuan Zhang, Nishika Karbhari, et al.
Pageof 72

Showing results (671-680 of 718) with videos related to

Sort By:
Pageof 72
Neuro-Oncology|February 28, 2026
DNA copy number patterns reveal prognostic markers and elucidate mechanisms of evolution in IDH-mutant astrocytomaKristen L Drucker, Arijit Panda, Paul A Decker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2024
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma ModelsSonia Jain, Jessica I Griffith, Kendra A Porath, et al.
Neuro-Oncology Advances|July 25, 2025
Dissecting the biology of gliomagenesis: Evaluating the interaction between <i>IDH</i> tumor mutation and germline variantsMatthew L Kosel, Paul A Decker, Thomas M Kollmeyer, et al.
Molecular Cancer Research : MCR|February 22, 2022
Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL InhibitionMasum Rahman, Ian Olson, Moustafa Mansour, et al.
Neuro-Oncology Advances|March 30, 2026
Comparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma, <i>IDH</i>-wildtypeDaniel H Lachance, Paul A Decker, Thomas M Kollmeyer, et al.
Molecular Cancer Therapeutics|January 15, 2024
Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis XenograftsJianxiong Ji, Sonja Dragojevic, Cameron M Callaghan, et al.
Journal of the National Cancer Institute|November 29, 2015
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of GlioblastomaShiv K Gupta, Sani H Kizilbash, Brett L Carlson, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 13, 2016
Development and impact of arrhythmias after the Norwood procedure: A report from the Pediatric Heart NetworkMatthew E Oster, Shan Chen, Nicholas Dagincourt, et al.
Medrxiv : the Preprint Server for Health Sciences|April 29, 2025
Cerebrospinal fluid D-2-hydroxyglutarate for IDH-mutant glioma: utility for detection versus monitoringCecile Riviere-Cazaux, Yuta Suzuki, Zain Kizilbash, et al.
Neuro-Oncology Advances|February 10, 2026
Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenograftsRachael A Vaubel, Wenjuan Zhang, Nishika Karbhari, et al.
Pageof 72